106 related articles for article (PubMed ID: 31694041)
21. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
22. [Predictive factors for clinically significant elevation of post-prostatectomy Gleason score in patients with biopsy Gleason score ≤7].
Guo X; Ma LM; Wu Y; Zhang YP; Li HL; Nong SJ; Guan YB; Huang YQ; Cai B
Zhonghua Nan Ke Xue; 2018 Dec; 24(12):1094-1099. PubMed ID: 32212489
[TBL] [Abstract][Full Text] [Related]
23. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
[TBL] [Abstract][Full Text] [Related]
24. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
25. Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.
Jo JK; Lee HS; Lee YI; Lee SE; Hong SK
Asian J Androl; 2015; 17(2):248-52. PubMed ID: 25432498
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
[TBL] [Abstract][Full Text] [Related]
27. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
28. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer.
Yoo C; Oh CY; Cho JS; Song C; Seo SI; Ahn H; Hwang TK; Cheon J; Lee KH; Kwon TG; Jung TY; Chung MK; Lee SE; Lee HM; Lee ES; Choi YD; Chung BH; Kim HJ; Kim WJ; Byun SS; Choi HY
J Korean Med Sci; 2011 Apr; 26(4):507-12. PubMed ID: 21468257
[TBL] [Abstract][Full Text] [Related]
30. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
31. High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy.
Porcaro AB; Petroziello A; Brunelli M; De Luyk N; Cacciamani G; Corsi P; Sebben M; Tafuri A; Tamanini I; Caruso B; Ghimenton C; Monaco C; Artibani W
Urol Int; 2016; 96(4):470-8. PubMed ID: 26845458
[TBL] [Abstract][Full Text] [Related]
32. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
[TBL] [Abstract][Full Text] [Related]
33. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
34. Pathological outcomes in men with prostate cancer who are eligible for active surveillance.
Wang SC; Chen CC; Yang CK; Hung SW; Jan YJ; Ou YC
J Chin Med Assoc; 2018 Apr; 81(4):348-351. PubMed ID: 28988599
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
36. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
37. Reducing the rate of biopsy Gleason undergrading may not improve biochemical recurrence rates in active surveillance candidates.
van den Bergh RC; Zargar H; Heijmink S; Bozin M; Murphy DG; van der Poel HG
Minerva Urol Nefrol; 2017 Aug; 69(4):359-365. PubMed ID: 28124869
[TBL] [Abstract][Full Text] [Related]
38. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
Verep S; Erdem S; Ozluk Y; Kilicaslan I; Sanli O; Ozcan F
Prostate; 2019 Sep; 79(13):1523-1529. PubMed ID: 31269285
[TBL] [Abstract][Full Text] [Related]
39. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study.
Beauval JB; Ploussard G; Soulié M; Pfister C; Van Agt S; Vincendeau S; Larue S; Rigaud J; Gaschignard N; Rouprêt M; Drouin S; Peyromaure M; Long JA; Iborra F; Vallancien G; Rozet F; Salomon L;
Urology; 2012 Sep; 80(3):656-60. PubMed ID: 22770616
[TBL] [Abstract][Full Text] [Related]
40. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known?
Vira MA; Guzzo T; Heitjan DF; Tomaszewski JE; D'Amico A; Wein AJ; Malkowicz SB
BJU Int; 2008 May; 101(10):1232-6. PubMed ID: 18419697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
